BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Operating Margin · Q3 FY2026 · quarter ended Sep 2026

Operating margin narrows to -8.0%

Operating margin was -8.0% in Q3 FY2026, down 2.0 pp from a year earlier. On a trailing-twelve-month basis it was -8.0%, down 27.9 pp year over year. Over 3 fiscal years it widened by 8.9 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 20 analysts of 18.6% for the fiscal year ending Dec 2026, up from 16.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-8.0%-19.2 pp QoQ
Last fiscal yearDec 2025
16.6%-0.4 pp YoY
LTMSep 2026
-8.0%-27.9 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.0 pp+12.5 pp+14.5 pp
1 year-0.4 pp+2.0 pp+2.4 pp
3 years+8.9 pp+20.1 pp+11.3 pp
5 years+23.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
16.6%
Year-over-year change
-0.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How BMRN compares with its peers on the latest reported figures

  • BMRN's LTM Sep 2026 operating margin of -8.0% is the 6th highest of the 11 companies compared; the peer median is -7.1%.
  • Its year-over-year change of -27.9 pp is the 9th highest of 11, against a peer median of +4.6 pp.
  • Over three fiscal years its change of +8.9 pp compares with a peer median of +94.1 pp.
BMRN Competitors Peer median
Operating Margin for BMRN and competitors
Company Period LTM level YoY 3-year change
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202633.9% -0.2 pp-8.8 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202620.8% +28.1 pp+89.2 pp
ASNDAscendis Pharma A/SLTM Sep 202618.4% +40.9 pp+1078.9 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202611.5% -29.2 pp+113.5 pp
PHARPharming Group N.V.LTM Mar 20266.3% +6.1 pp-3.3 pp
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-8.0% -27.9 pp+8.9 pp
TVTXTravere Therapeutics, Inc.LTM Sep 2026-20.5% +0.4 pp+279.4 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-58.9% -30.2 pp+29.4 pp
INSMInsmed IncorporatedLTM Jun 2026-71.9% +180.5 pp-7.7 pp
BBIOBridgeBio Pharma, Inc.LTM Jun 2026-76.2% +202.2 pp+546.3 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-83.9% +3.0 pp+99.1 pp
Peer median (excluding BMRN) -7.1%+4.6 pp+94.1 pp

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.85B2.1B2.42B2.85B3.22B
Cost of Revenue470.52M503.02M532.06M580.24M736.83M
Gross Profit1.38B1.59B1.89B2.27B2.48B
Gross Margin74.5%76.0%78.0%79.7%77.1%
Research & Development628.79M649.61M746.77M747.18M921.93M
Selling, General & Admin759.4M823.2M892.4M1.01B1.28B
Operating Expenses1.46B1.43B1.7B1.79B1.95B
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
EBITDA47.43M265.36M306.77M650.53M572.94M
EBITDA Margin2.6%12.7%12.7%22.8%17.8%
Operating Income(82.34M)160.97M185.77M484.21M533.48M
Operating Margin-4.5%7.7%7.7%17.0%16.6%
Interest Income10.48M18.03M58.34M74.88M74.9M
Interest Expense15.34M15.97M17.34M12.67M10.9M
Other Income / Expenses6.99M(11.4M)2.79M57.55M(51M)
Income Before Tax(75.35M)149.58M188.56M541.76M482.48M
Pre-Tax Margin-4.1%7.1%7.8%19.0%15.0%
Income Tax Expense(11.27M)8.02M20.92M114.9M133.58M
Net Income(64.08M)141.56M167.65M426.86M348.9M
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (Basic)(0.35)0.760.892.251.82
EPS (Diluted)(0.35)0.750.882.211.80
Weighted Avg Shares182.85M185.27M187.83M190.03M191.79M
Weighted Avg Shares (Diluted)182.85M188.96M191.6M196.71M197.39M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.